Clinical characteristics and long-term outcome of Takayasu arteritis in Iran: a multicentre study
Birmingham Vasculitis Activity Score (BVAS)
Indian Takayasu Clinical Activity Score (ITAS)
Takayasu arteritis
Vasculitis Damage Index (VDI)
outcome
remission
Iran
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
05
10
2019
accepted:
19
02
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
26
10
2021
Statut:
epublish
Résumé
This study aimed to evaluate the demographic, clinical, angiographic and prognostic characteristics of Takayasu
arteritis (TA) in Iran. A total of 75 patients with TA based on the American College of Rheumatology 1990 criteria for TA classification referred to the Rheumatology Centres, were followed-up from 1989 to 2019. Demographic, clinical, angiographic and prognostic characteristics were collected at baseline and last visit. The mean age was 31.9 ± 9.8 years at the disease onset. Female to male ratio was 14. The median latency in diagnosis was 24 months. Pulse discrepancy in the arms, blood pressure discrepancy in the arms, limb claudication, hypertension and constitutional symptoms were the most common clinical features. The most common angiographic type at the time of diagnosis was Type I (42.7%). The most frequent arterial lesion was stenosis (89.4%). Subclavian, carotid and aortic arteries were the most commonly involved arteries. New lesions developed in 28.6% of patients during the 5.25-year follow-up. Vasculitis-induced chronic damage was observed in all patients. Disease activity decreased and vascular damage remained stable throughout the follow-up period. The clinical features and angiographic type of TA in Iran are different from most Asian countries. Differences in angiographic and clinical features may lead to delayed diagnosis. The issue of delay in diagnosis should create awareness among health care providers that TA is not a very rare disease in Iranians and failure to pay attention to warning symptoms may delay the diagnosis.
Sections du résumé
Background/aim
This study aimed to evaluate the demographic, clinical, angiographic and prognostic characteristics of Takayasu
arteritis (TA) in Iran.
Materials and methods
A total of 75 patients with TA based on the American College of Rheumatology 1990 criteria for TA classification referred to the Rheumatology Centres, were followed-up from 1989 to 2019. Demographic, clinical, angiographic and prognostic characteristics were collected at baseline and last visit.
Results
The mean age was 31.9 ± 9.8 years at the disease onset. Female to male ratio was 14. The median latency in diagnosis was 24 months. Pulse discrepancy in the arms, blood pressure discrepancy in the arms, limb claudication, hypertension and constitutional symptoms were the most common clinical features. The most common angiographic type at the time of diagnosis was Type I (42.7%). The most frequent arterial lesion was stenosis (89.4%). Subclavian, carotid and aortic arteries were the most commonly involved arteries. New lesions developed in 28.6% of patients during the 5.25-year follow-up. Vasculitis-induced chronic damage was observed in all patients. Disease activity decreased and vascular damage remained stable throughout the follow-up period.
Conclusions
The clinical features and angiographic type of TA in Iran are different from most Asian countries. Differences in angiographic and clinical features may lead to delayed diagnosis. The issue of delay in diagnosis should create awareness among health care providers that TA is not a very rare disease in Iranians and failure to pay attention to warning symptoms may delay the diagnosis.
Identifiants
pubmed: 32093440
doi: 10.3906/sag-1910-19
pmc: PMC7379441
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
713-723Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Semin Arthritis Rheum. 2018 Apr;47(5):718-726
pubmed: 29096935
Clin Rheumatol. 2009 Feb;28(2):179-85
pubmed: 18797980
Arthritis Res Ther. 2017 May 25;19(1):107
pubmed: 28545566
Ann Intern Med. 1994 Jun 1;120(11):919-29
pubmed: 7909656
Clin Exp Rheumatol. 2008 May-Jun;26(3 Suppl 49):S9-15
pubmed: 18799047
Arthritis Rheum. 1997 Feb;40(2):371-80
pubmed: 9041949
Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S59-64
pubmed: 19646348
J Rheumatol. 2014 Dec;41(12):2439-46
pubmed: 25274886
Arthritis Care Res (Hoboken). 2017 Feb;69(2):278-285
pubmed: 27159262
Curr Opin Rheumatol. 2017 Jan;29(1):51-56
pubmed: 27748689
Arthritis Rheum. 1990 Aug;33(8):1129-34
pubmed: 1975175
Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S33-9
pubmed: 19646344
Arthritis Rheum. 2005 Feb 15;53(1):100-7
pubmed: 15696576
Rheumatology (Oxford). 2013 Oct;52(10):1795-801
pubmed: 23594468
Scand J Rheumatol. 2005 Jul-Aug;34(4):284-92
pubmed: 16195161
Presse Med. 2017 Jul - Aug;46(7-8 Pt 2):e197-e203
pubmed: 28756072
Mayo Clin Proc. 2013 Aug;88(8):822-30
pubmed: 23849994
Ann Rheum Dis. 2009 Dec;68(12):1827-32
pubmed: 19054820
Int J Cardiol. 1996 Aug;54 Suppl:S155-63
pubmed: 9119518
Medicine (Baltimore). 2010 Jan;89(1):1-17
pubmed: 20075700
Ann Rheum Dis. 2007 Mar;66(3):283-92
pubmed: 16728460